A patient with a blood pressure of 158/98 mmHg should be started on which antihypertensive medication?

Initial Antihypertensive Therapy for BP 158/98 mmHg

Start combination therapy with two first-line agents: a RAS blocker (ACE inhibitor or ARB) plus either a dihydropyridine calcium channel blocker or a thiazide/thiazide-like diuretic, preferably as a fixed-dose single-pill combination. 1

Rationale for Combination Therapy

Your patient has Stage 2 hypertension (BP >140/90 mmHg and >20/10 mmHg above target of <130/80 mmHg). 1

• Combination therapy is superior to monotherapy for most patients with confirmed hypertension at this level because it achieves faster BP control and improves medication adherence. 1
• The 2024 ESC guidelines explicitly recommend combination BP-lowering treatment as initial therapy for confirmed hypertension ≥140/90 mmHg. 1
• The 2017 ACC/AHA guidelines support initiating two first-line agents when BP is >20/10 mmHg above target, which applies to your patient (158/98 vs target <130/80). 1

Preferred Drug Combinations

First choice: RAS blocker + calcium channel blocker OR RAS blocker + thiazide diuretic 1, 2

Specific examples:

• ACE inhibitor (enalapril) + dihydropyridine CCB (amlodipine) 2
• ARB (candesartan) + dihydropyridine CCB (amlodipine) 2
• ACE inhibitor + thiazide-like diuretic (chlorthalidone or indapamide) 1, 2
• ARB + thiazide-like diuretic (chlorthalidone or indapamide) 1, 2

Why These Specific Agents?

• ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide/thiazide-like diuretics have demonstrated the most effective reduction of both BP and cardiovascular events, making them the recommended first-line treatments. 1
• Thiazide-like diuretics (chlorthalidone, indapamide) may provide optimal first-step therapy, particularly chlorthalidone which showed superior outcomes in large trials. 1
• Fixed-dose single-pill combinations are strongly preferred over separate pills because they improve adherence and BP control. 1

Treatment Target

Target BP: 120-129/<80 mmHg 1

• The 2024 ESC guidelines recommend targeting systolic BP of 120-129 mmHg in most adults, provided treatment is well tolerated. 1
• If this target cannot be achieved due to poor tolerance, use the "as low as reasonably achievable" (ALARA) principle. 1
• For patients <65 years, aim for <130/80 mmHg at minimum. 2

Critical Pitfalls to Avoid

Do NOT combine two RAS blockers (ACE inhibitor + ARB together) - this is explicitly not recommended. 1

Do NOT use beta-blockers as first-line monotherapy unless there are compelling indications (angina, post-MI, heart failure with reduced ejection fraction, or heart rate control needed). 1 Beta-blockers are significantly less effective than diuretics for stroke and cardiovascular event prevention. 1

Do NOT start with monotherapy at this BP level - your patient's BP is too far above target (>20/10 mmHg) to justify single-agent therapy. 1

Monitoring Considerations

• Assess for secondary hypertension if the patient is <40 years old (unless obese, then screen for obstructive sleep apnea first). 1
• Confirm diagnosis with home BP monitoring or 24-hour ambulatory monitoring before initiating therapy, as office readings may overestimate true BP. 3
• Evaluate for target organ damage and cardiovascular risk factors to guide intensity of therapy. 2

Lifestyle Modifications (Concurrent with Pharmacotherapy)

Initiate immediately alongside medications: 1, 2

• Dietary sodium restriction (<2g/day) and potassium supplementation
• Weight loss if overweight
• Physical activity (150 minutes/week moderate intensity)
• Alcohol limitation or cessation
• Smoking cessation
• Limit free sugar to <10% of energy intake